# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jack London (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET010-SYN-TD
- Date: 1915-10-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe-Ibe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Ten-week review. **S**

## History of present illness

Mr. London has had no alcohol for six weeks, since the evening of the ankle sprain. He takes naltrexone and losartan 100 mg every morning; he has had no dizziness. His home readings average 124/78. He eats two meals a day now, and has not missed a meal or been unwell for weeks. The ankle has healed and he is riding again. He writes every morning and has finished a long story. He has kept up weekly counseling. **S**

| Element | Detail |
|---|---|
| Alcohol | None for six weeks; PEth 8 ng/mL |
| Potassium and creatinine | 5.0 mmol/L; 1.95 mg/dL (eGFR 44) four weeks after losartan 100 mg |
| Home readings | Average 124/78 mmHg |
| Ankle | Healed |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; eating regularly |
| Cardiovascular | Negative | No dizziness or ankle swelling |
| Genitourinary | Negative | No urinary or genital symptoms |
| Psychiatric | Negative | Mood good; cravings rare; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet once daily **S**
- Thiamine 100 mg oral tablet once daily **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen **S**
- Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines **S**
- Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily **S**
- Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/80 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 81.4 kg; BMI 27.2 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 5 mmol/L; Bicarbonate (total CO2): 23 mmol/L; Creatinine: 1.95 mg/dL (high); eGFR (CKD-EPI 1910): 44 mL/min/1.73 m² (low); PEth (alcohol marker): 8 ng/mL. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.6 mmol/L at baseline, 5 mmol/L at this visit **S**
- Bicarbonate (total CO2): 22 mmol/L at baseline, 23 mmol/L at this visit **S**
- Creatinine: 1.98 mg/dL (high) at baseline, 1.95 mg/dL (high) at this visit **S**
- eGFR (CKD-EPI 1910): 43 mL/min/1.73 m² (low) at baseline, 44 mL/min/1.73 m² (low) at this visit **S**
- PEth (alcohol marker): 410 ng/mL (high) at baseline, 8 ng/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 126/80, pulse 72; weight 81.4 kg |
| Cardiovascular | Regular rhythm; no edema |
| Musculoskeletal | Right ankle normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3b A2** (N18.32). Stable on losartan 100 mg: creatinine 1.95 mg/dL, eGFR 44, potassium 5.0 mmol/L at the upper end of normal. With six weeks of abstinence, regular meals and no diabetes, the risk of ketoacidosis from an SGLT2 inhibitor is now low, and KDIGO recommends one for his eGFR and albuminuria; it also lowers potassium and uric acid a little. **S**
   - Dapagliflozin 10 mg every morning from today.
   - Sick-day rules in writing: hold dapagliflozin on any day he cannot eat or drink normally, with vomiting or diarrhea, before surgery, or if he drinks heavily again.
   - Potassium and creatinine in two weeks; an early fall in eGFR of up to 30 percent is expected and accepted.
2. **Right ankle sprain** (S93.401A). Healed. **S**
   - No further treatment.
3. **Alcohol use disorder, severe, in early recovery** (F10.20). PEth 8 ng/mL confirms abstinence. Safety reviewed: no thoughts of suicide or self-harm, firearms locked, 988 card carried. **S**
   - Continue naltrexone and counseling.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated device, average of readings) | Every visit | Completed today | 126/80 mmHg; home average 124/78 |
| Laboratory | Potassium and creatinine after starting or changing losartan or an SGLT2 inhibitor | Two to four weeks after each start or change | Completed today | Four weeks after losartan 100 mg: potassium 5.0 mmol/L, creatinine 1.95 mg/dL; dapagliflozin started today, recheck in two weeks |
| Laboratory | Creatinine with eGFR and urine albumin-to-creatinine ratio | G3b A2: twice a year, and at each medicine check | Completed today | eGFR 44; urine albumin due at twelve weeks |
| Laboratory | Electrolytes and bicarbonate | With each kidney test | Completed today | Sodium 139; bicarbonate 23 mmol/L |
| Medication safety | SGLT2 inhibitor safety: sick-day rules, ketoacidosis, genital infection, volume | At the start and every visit | Completed today | Started today after six weeks of abstinence and regular meals; sick-day rules in writing; genital hygiene explained |
| Medication safety | Medication reconciliation: no NSAIDs, kidney dosing, contrast safety | Every visit | Completed today | No NSAIDs; dapagliflozin added |
| Self-management | Lifestyle: sodium below 2 g a day, activity, diet, weight | Every visit | Completed today | Riding and swimming; less salt |
| Survey | Drinking since the last visit (self-report) | Every visit | Completed today | None for six weeks |
| Laboratory | PEth | At baseline and every four to six weeks in early recovery | Completed today | 8 ng/mL: abstinence |
| Laboratory | Liver tests (AST, ALT, GGT) on naltrexone | At baseline, at four to six weeks, then every few months | Up to date | Normal-range at six weeks; next at twelve weeks |
| Medication safety | Naltrexone safety: opioid use, nausea, wallet card | Every visit | Completed today | No nausea; no opioid |
| Referral | Addiction-focused counseling and mutual help | Weekly in early recovery | Completed today | Weekly sessions kept |
| Survey | Suicide-risk review, firearms storage, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked; 988 card carried |
| Self-management | Tobacco use and readiness to stop | Every visit | Completed today | About ten a day; thinking about a quit date |

## Goal progress

- Find out how much kidney function is lost, how long it has been so, and why. Outcome by 1915-08-18: Chronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspected. **S**
- Stop drinking safely, and stay stopped. In progress; target 1916-02-02. **S**
- Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/80. In progress; target 1916-02-02. **S**
- Urine albumin down by at least 30 percent. In progress; target 1915-10-27. **S**
- No anti-inflammatory pain medicines, and pain controlled. In progress; target 1915-10-27. **S**
- Keep the morning writing hours. In progress; target 1915-10-27. **S**

## Medication changes

- Started: Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgery **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026), Aether Forge
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Twelve-week review in two weeks with potassium, creatinine, urine albumin, liver tests, PEth, AUDIT, PHQ-9 and GAD-7. Counseling weekly. The clinic or 988 at any hour. **S**
- Next scheduled visit 1915-10-27: twelve-week review: kidney function after the SGLT2 inhibitor, urine albumin, liver tests, AUDIT, mood, safety and the plan ahead. **S**
